Skip to main content

Table 4 Mortality rates of patients with eGFR < 30 or dialysis who received levosimendan versus dobutamine alone

From: Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study

Outcomes Event (%) Levosimendan vs. dobutamine
Levosimendan Dobutamine HR (95% CI) P value
Before PSM patient numbers 52 374   
 In-hospital mortality 14 (26.9) 114 (30.5) 0.76 (0.44–1.32) 0.330
 5-day mortality 5 (9.6) 45 (12.0) 0.79 (0.31–1.98) 0.611
 14-day mortality 11 (21.2) 76 (20.3) 1.01 (0.54–1.91) 0.968
 30-day mortality 11 (21.2) 104 (27.8) 0.73 (0.39–1.37) 0.330
 90-day mortality 14 (26.9) 132 (35.3) 0.72 (0.42–1.25) 0.247
 180-day mortality 18 (34.6) 148 (39.6) 0.83 (0.51–1.36) 0.457
After PSM patient numbers 43 81   
 In-hospital mortality 13 (30.2) 30 (37.0) 0.67 (0.36–1.26) 0.212
 5-day mortality 4 (9.3) 10 (12.3) 0.76 (0.26–2.22) 0.611
 14-day mortality 10 (23.3) 21 (25.9) 0.87 (0.42–1.80) 0.707
 30-day mortality 10 (23.3) 28 (34.6) 0.65 (0.30–1.37) 0.254
 90-day mortality 13 (30.2) 34 (42.0) 0.68 (0.35–1.31) 0.248
 180-day mortality 17 (39.5) 36 (44.4) 0.84 (0.45–1.55) 0.573
  1. HR hazard ratio, CI confidence interval, PSM propensity score matching